What's the most recent regulatory action in Infection due to anaerobic bacteria?

Most recent: Cleocin T — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/infection-due-to-anaerobic-bacteria.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Infection due to anaerobic bacteria — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Infection due to anaerobic bacteria (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Infection due to anaerobic bacteria, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cleocin T	CLINDAMYCIN PHOSPHATE	Pfizer	Lincosamide Antibacterial		1972-01-01
Cleocin	clindamycin	Generic (originally Upjohn/Pfizer)	Lincosamide antibiotic	50S ribosomal protein L10	1970-01-01
Metro I.V. In Plastic Container	METRONIDAZOLE	Baxter	Nitroimidazole Antimicrobial [EPC]		1963-01-01
Metronidazol	Metronidazol	University of Oslo		Thioredoxin reductase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-23 — Cleocin T · FDA · approved · US
2026-03-18 — Cleocin T · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Baxter · 1 drug in Infection due to anaerobic bacteria
Generic (originally Upjohn/Pfizer) · 1 drug in Infection due to anaerobic bacteria
Pfizer · 1 drug in Infection due to anaerobic bacteria
University of Oslo · 1 drug in Infection due to anaerobic bacteria

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Infection due to anaerobic bacteria:

Cite this brief

Drug Landscape (2026). Infection due to anaerobic bacteria — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/infection-due-to-anaerobic-bacteria. Accessed 2026-06-10.

Infection due to anaerobic bacteria full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing